Maxcyte (MXCT) Accumulated Depreciation (2020 - 2026)

Maxcyte (MXCT) has reported Accumulated Depreciation for 7 consecutive years, with $17.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Depreciation rose 5.35% year-over-year to $17.4 million in Q2 2026; TTM through Jun 2026 was $17.4 million, a 5.35% increase from a year earlier, with the FY2025 full-year figure at $17.3 million, up 27.02% from the prior year.
• Accumulated Depreciation was $17.4 million for Q2 2026 at Maxcyte, down from $18.3 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $18.3 million in Q1 2026 and troughed at $4.8 million in Q1 2022.
• A 5-year average of $11.6 million and a median of $11.6 million in 2024 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation surged 65.6% in 2023 and grew 5.35% in 2026, its largest moves.
• Over 5 years, Accumulated Depreciation stood at $6.3 million in 2022, then surged by 63.92% to $10.3 million in 2023, then jumped by 32.14% to $13.6 million in 2024, then advanced by 27.02% to $17.3 million in 2025, then increased by 0.78% to $17.4 million in 2026.
• The last three Accumulated Depreciation figures came in at $17.4 million (Q2 2026), $18.3 million (Q1 2026), and $17.3 million (Q4 2025), per Business Quant data.